Publications | PubMed=4369887; DOI=10.1073/pnas.71.8.3283; PMCID=PMC388669 Klein G., Lindahl T.L., Jondal M., Leibold W., Menezes J., Nilsson K., Sundstrom C. Continuous lymphoid cell lines with characteristics of B cells (bone-marrow-derived), lacking the Epstein-Barr virus genome and derived from three human lymphomas. Proc. Natl. Acad. Sci. U.S.A. 71:3283-3286(1974) PubMed=171663; DOI=10.1073/pnas.72.9.3518; PMCID=PMC433026 Steinitz M., Klein G. Comparison between growth characteristics of an Epstein-Barr virus (EBV)-genome-negative lymphoma line and its EBV-converted subline in vitro. Proc. Natl. Acad. Sci. U.S.A. 72:3518-3520(1975) PubMed=179629 Menezes J., Leibold W., Klein G., Clements G.B. Establishment and characterization of an Epstein-Barr virus (EBV)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma. Biomedicine 22:276-284(1975) PubMed=62724; DOI=10.1002/ijc.2910180513 Klein G., Zeuthen J., Terasaki P.I., Billing R.J., Honig R., Jondal M., Westman A., Clements G.B. Inducibility of the Epstein-Barr virus (EBV) cycle and surface marker properties of EBV-negative lymphoma lines and their in vitro EBV-converted sublines. Int. J. Cancer 18:639-652(1976) PubMed=175026; DOI=10.1002/ijc.2910170203 Fresen K.-O., zur Hausen H. Establishment of EBNA-expressing cell lines by infection of Epstein-Barr virus (EBV)-genome-negative human lymphoma cells with different EBV strains. Int. J. Cancer 17:161-166(1976) PubMed=6245632; DOI=10.1007/BF01320759 Lui S.W.-L., Ng M.-H. Glycoproteins and sialyl transferase of human B lymphoblastoid cell lines. Arch. Virol. 63:31-41(1980) PubMed=7316467; DOI=10.1111/j.1469-1809.1980.tb00953.x Povey S., Jeremiah S., Arthur E., Steel M., Klein G. Differences in genetic stability between human cell lines from patients with and without lymphoreticular malignancy. Ann. Hum. Genet. 44:119-133(1980) PubMed=6286763; DOI=10.4049/jimmunol.129.3.1336 Benjamin D., Magrath I.T., Maguire R.T., Janus C., Todd-Kulikowsk H.D., Parsons R.G. Immunoglobulin secretion by cell lines derived from African and American undifferentiated lymphomas of Burkitt's and non-Burkitt's type. J. Immunol. 129:1336-1342(1982) PubMed=6600440; DOI=10.1007/BF02617996 Uittenbogaart C.H., Cantor Y., Fahey J.L. Growth of human malignant lymphoid cell lines in serum-free medium. In Vitro 19:67-72(1983) PubMed=6231253; DOI=10.1002/ijc.2910330407 Ehlin-Henriksson B., Klein G. Distinction between Burkitt lymphoma subgroups by monoclonal antibodies: relationships between antigen expression and type of chromosomal translocation. Int. J. Cancer 33:459-463(1984) PubMed=3518877; DOI=10.3109/07357908609038260 Fogh J. Human tumor lines for cancer research. Cancer Invest. 4:157-184(1986) PubMed=3495441; DOI=10.1002/eji.1830170503 Kanowith-Klein S., Saxon A., Uittenbogaart C.H. Constitutive production of B cell differentiation factor-like activity by human T and B cell lines. Eur. J. Immunol. 17:593-598(1987) PubMed=1915267; DOI=10.1002/j.1460-2075.1991.tb07837.x; PMCID=PMC452998 Farrell P.J., Allan G.J., Shanahan F., Vousden K.H., Crook T. p53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO J. 10:2879-2887(1991) PubMed=8344493; DOI=10.1096/fasebj.7.10.8344493 Bhatia K.G., Goldschmidts W., Gutierrez M.I., Gaidano G., Dalla-Favera R., Magrath I.T. Hemi- or homozygosity: a requirement for some but not other p53 mutant proteins to accumulate and exert a pathogenetic effect. FASEB J. 7:951-956(1993) PubMed=8515068; DOI=10.4049/jimmunol.150.12.5418 Jain V.K., Judde J.-G., Max E.E., Magrath I.T. Variable IgH chain enhancer activity in Burkitt's lymphomas suggests an additional, direct mechanism of c-myc deregulation. J. Immunol. 150:5418-5428(1993) PubMed=8558920 Dirks W.G., Zaborski M., Jager K., Challier C., Shiota M., Quentmeier H., Drexler H.G. The (2;5)(p23;q35) translocation in cell lines derived from malignant lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines. Leukemia 10:142-149(1996) PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4 Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J. Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines. Leuk. Res. 24:255-262(2000) PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1 Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J. Corrigendum to: Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24 (2000), 255-262. Leuk. Res. 25:275-278(2001) PubMed=20054396; DOI=10.1038/nature08638; PMCID=PMC2845535 Davis R.E., Ngo V.N., Lenz G., Tolar P., Young R.M., Romesser P.B., Kohlhammer H., Lamy L., Zhao H., Yang Y.-D., Xu W.-H., Shaffer A.L. 3rd, Wright G., Xiao W.-M., Powell J.I., Jiang J.-K., Thomas C.J., Rosenwald A., Ott G., Muller-Hermelink H.-K., Gascoyne R.D., Connors J.M., Johnson N.A., Rimsza L.M., Campo E., Jaffe E.S., Wilson W.H., Delabie J., Smeland E.B., Fisher R.I., Braziel R.M., Tubbs R.R., Cook J.R., Weisenburger D.D., Chan W.-C., Pierce S.K., Staudt L.M. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463:88-92(2010) PubMed=23292937; DOI=10.1073/pnas.1205299110; PMCID=PMC3557051 Zhang J., Grubor V., Love C.L., Banerjee A., Richards K.L., Mieczkowski P.A., Dunphy C., Choi W.W.-L., Au W.Y., Srivastava G., Lugar P.L., Rizzieri D.A., Lagoo A.S., Bernal-Mizrachi L., Mann K.P., Flowers C.R., Naresh K.N., Evens A.M., Gordon L.I., Czader M.B., Gill J.I., Hsi E.D., Liu Q.-Q., Fan A., Walsh K., Jima D., Smith L.L., Johnson A.J., Byrd J.C., Luftig M.A., Ni T., Zhu J., Chadburn A., Levy S., Dunson D.B., Dave S.S. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc. Natl. Acad. Sci. U.S.A. 110:1398-1403(2013) PubMed=23257783; DOI=10.1038/leu.2012.367 Wenzel S.-S., Grau M., Mavis C., Hailfinger S., Wolf A., Madle H., Deeb G., Dorken B., Thome M., Lenz P., Dirnhofer S., Hernandez-Ilizaliturri F.J., Tzankov A., Lenz G. MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma. Leukemia 27:1381-1390(2013) PubMed=25485619; DOI=10.1038/nbt.3080 Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M. A comprehensive transcriptional portrait of human cancer cell lines. Nat. Biotechnol. 33:306-312(2015) PubMed=25877200; DOI=10.1038/nature14397 Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M. A resource for cell line authentication, annotation and quality control. Nature 520:307-311(2015) PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878 Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C. TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression. Genome Med. 7:118.1-118.7(2015) PubMed=26787899; DOI=10.1073/pnas.1524677113; PMCID=PMC4747717 Dekker J.D., Park D., Shaffer A.L. 3rd, Kohlhammer H., Deng W., Lee B.-K., Ippolito G.C., Georgiou G., Iyer V.R., Staudt L.M., Tucker H.O. Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1. Proc. Natl. Acad. Sci. U.S.A. 113:E577-E586(2016) PubMed=29416618; DOI=10.18632/oncotarget.20378; PMCID=PMC5787470 Liu W., Chen J., Tamayo A.T., Ruan C.-G., Li L., Zhou S.-H., Shen C., Young K.H., Westin J., Davis R.E., Hu S.-M., Medeiros L.J., Ford R.J. Jr., Pham L.V. Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma. Oncotarget 9:346-360(2018) PubMed=29666304; DOI=10.1158/1078-0432.CCR-17-3004 Pham L.V., Huang S.-J., Zhang H., Zhang J., Bell T., Zhou S.-H., Pogue E., Ding Z.-Y., Lam L., Westin J., Davis R.E., Young K.H., Medeiros L.J., Ford R.J. Jr., Nomie K., Zhang L., Wang M. Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas. Clin. Cancer Res. 24:3967-3980(2018) PubMed=30165192; DOI=10.1016/j.canlet.2018.08.020 Qu C.-J., Kunkalla K., Vaghefi A., Frederiksen J.K., Liu Y.-D., Chapman J.R., Blonska M., Bernal-Mizrachi L., Alderuccio J.P., Lossos I.S., Landgraf R., Vega-Vazquez F. Smoothened stabilizes and protects TRAF6 from degradation: a novel non-canonical role of smoothened with implications in lymphoma biology. Cancer Lett. 436:149-158(2018) PubMed=31160637; DOI=10.1038/s41598-019-44491-x; PMCID=PMC6547646 Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K.G., Uphoff C.C., Drexler H.G. The LL-100 panel: 100 cell lines for blood cancer studies. Sci. Rep. 9:8218-8218(2019) |